Roche

C4 Therapeutics and Roche have partnered since January 2016 to advance research in targeted protein degradation. The initial strategic collaboration outlines plans for C4T to develop degraders targeting a specified set of proteins through defined pre-clinical or early clinical milestones and provides Roche with exclusive options for worldwide rights to continue development and commercialize products arising from the collaboration.

In April 2026, C4T and Roche expanded the long-term partnership by signing a new agreement focused on discovering and developing degrader-antibody conjugates (DACs), an emerging modality that leverages the specificity and catalytic efficiency of degraders with the delivery capabilities of antibody-drug conjugates (ADCs). Under the joint research plan, C4T and Roche collaborate on two programs to develop DACs against undisclosed oncology targets exclusive to the collaboration. C4T will use its proprietary TORPEDO^® platform to design degrader payload candidates. Roche will select and design the antibody as well as conjugate the antibody. Roche will be responsible for advancing DAC candidates through preclinical and clinical development as well as commercialization.